68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Prostate Cancer
Interventions
DRUG

68Ga-Labeled PSMA

All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.

DRUG

Non-labeled PSMA

Patient will be injected with microdose (\<100 ug) of THP-PSMA

Trial Locations (1)

Unknown

Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

NanoMab Technology (UK) Limited

INDUSTRY

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER